Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Could be a useful way of crystallising a loss to offset against a possible CGT liability elsewhere. Anyway, tomorrow is another day.
I doubt it's a dump per se - second 500k attracted a slightly higher price than the first, and the sp is weak at the moment so a 1 million dump would have hit it harder. Also the bid on smaller quantities rose after those transactions. But hey, who knows?!
Don't forget the needle-free delivery - LD was surprised at the number of people who had a deep fear of needles. Needle-free would be a big plus on top of efficacy etc.
73 percent of 87 is 63 or 64, depending which side of the decimal point you fall. Impressive.
Andysel you say 'the lab has its first contract, the official launch of the Lab is in September' - translates as 'the lab has one contract which expires in September.'
Beyond that, nothing. The launch is going to be a very quiet party as things stand.
Some usual suspects have been curiously (and pleasantly) absent since that last RNS, but I'm sure that's just coincidence. They must just have decided to have a couple of weeks off.
The difference is that if the lth here say anything like that, you get an invasion of 'balanced' posters screaming 'happy clapper', but when a 'chartist' says it it's seen as somehow informed. Nowt as que er as folk!
Zak Mir is about as reliable as an Austin Allegro, but we shall see.
Probably not.
Reminiscent of the David Carradine King Fu series. For 'crumbs' Read 'grasshopper.'
Meanwhile one can peruse the 'other side' and stand in moderate amazement at the cess pit of spite and bile being stirred around by some who would tell you they are 'balanced.' They seem to be missing an 'un', but then reality is subjective I suppose.
After 20 years, 'now undergoing pre-clinical research in the US'. Not exactly on the cusp of human trials.
Fat fingers!
The contract announced in mid july for the lab says 'This defined work programme involves a multi-stage project and is expected to complete at the end of September 2023.'
So any income from it will stop in 8 weeks maximum.
If ever the term 'DYOR' needed an illustration, that video is it.
Given how famous the company is for slipping timescales, it's interesting to see that a safety committee review 'scheduled to take place in August' has presumably already been and gone before the end of July, last week at the latest, and most importantly has given the cohort expansion a thumbs-up. Normally when Scancell say 'scheduled for August' half the watchers think 'that means September or October' and the other half think 'August 23 or August 24?'
Does this earlier than expected move show positive urgency?
Also, the 10th July rns said they had recruited three patients for full dose Modi-1 in combination with nivolumab and 'Subject to a safety committee review....this cohort will be expanded to 21 patients in both head and neck and renal cancer.'
Today's rns says 'expansion into two cohorts of patients with renal or head and neck cancer who receive CPI as standard of care. 21 patients will be recruited into each cohort.'
Does that mean the numbers have doubled?
Any way up, it seems Scancell are at or pretty near the front of the queue for trial patients which is good for both sides.
Well noticed JB1 - Scancell running ahead of schedule is significant indeed!
That's a little harsh. I'm sure the reason none of the 'usuals' have appeared is because being pro traders they won't bother logging in to read Monday morning RNSs. They probably have a lie in at the start of the week.
By 'tumour regression' are they talking shrinkage in excess of 30 percent as per the definition?
That looks encouraging to me. But as ever, dyor and act as you think best. Different opinions are available, some more valuable than others.